Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 6/20 | 0.68 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.68 |
| ▸ | TSHR | P16473 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 2/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.37 |
| ▸ | CES1 | P23141 | 2/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL598952 | 0.97 | CYP1A2 (0.65) | CYP1A2CYP2A6TSHRALDH1A1HPGD | |
| SCHEMBL599477 | 0.83 | CYP1A2 (0.87) | CYP1A2CYP2A6TSHRALDH1A1HPGD | |
| SCHEMBL6705797 | 0.83 | CYP1A2 (0.87) | CYP1A2CYP2A6TSHRALDH1A1HPGD | |
| SCHEMBL424167 | 0.83 | CYP1A2 (1.00) | CYP1A2CYP2A6TSHRALDH1A1HPGD | |
| SCHEMBL597709 | 0.83 | TSHR (0.52) | CYP1A2CYP2A6TSHRALDH1A1HPGD | |
| SCHEMBL29463284 | 0.83 | CYP1A2 (1.00) | CYP1A2CYP2A6TSHRALDH1A1HPGD | |
| SCHEMBL9010933 | 0.81 | CYP1A2 (0.83) | CYP1A2CYP2A6TSHRALDH1A1HPGD | |
| SCHEMBL15224424 | 0.80 | CYP1A2 (0.59) | CYP1A2CYP2A6TSHRALDH1A1HPGD | |
| SCHEMBL29293329 | 0.78 | CYP1A2 (0.52) | CYP1A2CYP2A6TSHRALDH1A1HPGD | |
| SCHEMBL3961404 | 0.78 | CYP1A2 (0.59) | CYP1A2CYP2A6TSHRALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240407250-A1 | COMPOSITION FOR ORGANIC ELECTROLUMINESCENT ELEMENT, METHOD FOR PRODUCING ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, AND ILLUMINATOR | MITSUBISHI CHEMICAL CORPORATION (JP) | 2024-12-05 | — | — | US | disclosed |
| WO-2023153161-A1 | COMPOSITION FOR ORGANIC ELECTROLUMINESCENT ELEMENT, METHOD FOR MANUFACTURING ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICEELECTROLUMINESCENCE ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICE | 三菱ケミカル株式会社 | 2023-08-17 | — | — | WO | disclosed |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8114997-B2 | N4-acylcytosine nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| US-RE42015-E1 | N4-acylcytosine-1,3-dioxolane nucleosides for treatment of viral infections | PHARMASSET, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | PHARMASSET, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| EP-1569652-A4 | N SP 4 /SP-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL IINFECTIONS | PHARMASSET INC (US) | 2008-07-02 | — | — | EP | disclosed |
| US-7314946-B2 | (2-cyclopentenyl)chlorosilanes and their preparation methods | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2008-01-01 | — | — | US | disclosed |
| US-20070191622-A1 | (2-Cyclopentenyl)chlorosilanes and their preparation methods | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY | 2007-08-16 | — | — | US | disclosed |
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | GILEAD PHARMASSET LLC | 2007-04-05 | — | — | US | disclosed |
| US-4382034-A | Process for the preparation of dianthraquinonylamines | BAYER AKTIENGESELLSCHAFT (DE) | 1983-05-03 | — | — | US | disclosed |
| EP-0049381-A1 | Process for the preparation of dianthraquinonyl amines | BAYER AG (DE) | 1982-04-14 | — | — | EP | disclosed |
| EP-0006203-B1 | PROCESS FOR THE PREPARATION OF AMINODIOXYANTHRACENES | BAYER AG (DE) | 1981-09-16 | — | — | EP | disclosed |
| EP-0006203-A1 | Process for the preparation of aminodioxyanthracenes | BAYER AG (DE) | 1980-01-09 | — | — | EP | disclosed |
| US-4163747-A | Process for the preparation of 1-alkylamino-anthraquinones | BAYER AKTIENGESELLSCHAFT (DE) | 1979-08-07 | — | — | US | disclosed |
| US-4102906-A | Process for preparing α-amino-β'-nitroanthraquinones | BAYER AKTIENGESELLSCHAFT (DE) | 1978-07-25 | — | — | US | disclosed |
| US-4076736-A | Preparation of aminoanthraquinones from nitroanthraquinones | BAYER AKTIENGESELLSCHAFT (DT) | 1978-02-28 | — | — | US | disclosed |
| US-4054587-A | Preparation of chloroanthraquinones from nitroanthraquinones | BAYER AKTIENGESELLSCHAFT (DT) | 1977-10-18 | — | — | US | disclosed |
| US-3933867-A | Process for the preparation of 1-aminoanthraquinone | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-20 | — | — | US | disclosed |
| US-3933868-A | Process for the preparation of 1,5- and 1,8-diamino-anthraquinone | BAYER AKTIENGESELLSCHAFT (DT) | 1976-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078080-A1 | N4-Acylcytosine Nucleosides for Treatment of Viral Infections | ENTPD5, DUT, NT5C3B | CYP1A2 1240/4885CYP2A6 1327/4885TSHR 4176/4885 |
| US-20090176730-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, NT5C3B, PNP | CYP1A2 1415/4885CYP2A6 1388/4885TSHR 4434/4885 |
| US-20070191622-A1 | (2-Cyclopentenyl)chlorosilanes and their preparation methods | DHPS, SFN, CSDE1 | CYP1A2 1467/4885CYP2A6 1977/4885TSHR 4764/4885 |
| US-20120202766-A1 | N4-ACYLCYTOSINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS | ENTPD5, DUT, NT5C3B | CYP1A2 1174/4885CYP2A6 1296/4885TSHR 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.